Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer (scientific article)

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

Q28142158

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

Q29615226

Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group

Q33539260

Associations between energy balance and body mass index and risk of breast carcinoma in women from diverse racial and ethnic backgrounds in the U.S.

Q33855674

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial

Q34208463

Breast cancer and hormone-replacement therapy in the Million Women Study

Q34223870

The Women's Health Initiative recruitment methods and results

Q34272010

The women's health initiative observational study: baseline characteristics of participants and reliability of baseline measures

Q34272017

Functional role of estrogen metabolism in target cells: review and perspectives

Q34457135

Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up

Q36115140

Abnormal oxidative metabolism of estradiol in women with breast cancer.

Q36295160

Estradiol 16 alpha-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans

Q37543007

Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women

Q38480036

16 alpha-hydroxylation of estradiol: a possible risk marker for breast cancer

Q39503292

Physical activity and cancer etiology: associations and mechanisms

Q40825433

Estrogens and breast cancer

Q41270267

Weight gain in women diagnosed with breast cancer

Q41465895

Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women.

Q41674609

Endogenous estrogen and postmenopausal breast cancer: a quantitative review

Q41680221

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

Q41719517

The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth

Q42800609

Influence of body weight on estradiol metabolism in young women

Q43567786

Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women

Q43609230

Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies

Q43963634

Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection

Q44244686

Predictors of the plasma ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups

Q44456406

Relationship between long durations and different regimens of hormone therapy and risk of breast cancer

Q44489759

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

Q44507925

The impact of dose and route of estrogen administration on the somatotropic axis in normal women

Q44616475

Estrogen metabolites and the risk of breast cancer in older women

Q44625494

Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation.

Q45965243

Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States).

Q47175609

Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk

Q47229226

Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years

Q47606588

Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women.

Q50867313

Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk.

Q53476793

Design of the Women’s Health Initiative Clinical Trial and Observational Study

Q56483522

Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women.

Q57037954

Implementation of the women's health initiative study design

Q57055364

Role of Estradiol Metabolism and CYP1A1 Polymorphisms in Breast Cancer Risk

Q57665716

Monoclonal antibody-based enzyme immunoassay for simultaneous quantification of 2- and 16α-hydroxyesterone in urine

Q57665754

Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study

Q57752411

Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group

Q58217528

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

obesity

Q12174

P304

page(s)

1292-1301

P577

publication date

2006-03-01

P1433

published in

International Journal of Cancer

Q332492

P1476

title

Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer

P478

volume

118

Reverse relations

cites work (P2860)

Q37694024	Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women's Health Initiative Observational Study
Q42516483	Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women
Q27012792	Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status
Q36426024	Body mass index and risk of ovarian cancer
Q36925454	Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women
Q34068274	Comparison of estrogens and estrogen metabolites in human breast tissue and urine.
Q43184870	Effect of flaxseed consumption on urinary levels of estrogen metabolites in postmenopausal women
Q35769029	Estrogen metabolism and risk of breast cancer in postmenopausal women.
Q34574141	Estrogen metabolite ratio: Is the 2-hydroxyestrone to 16α-hydroxyestrone ratio predictive for breast cancer?
Q36113238	Exogenous estrogen protects mice from the consequences of obesity and alcohol
Q36792134	Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk
Q36385015	Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women's Health Initiative Hormone Therapy Trial
Q35469275	Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer
Q80272756	Moderate coffee and alcohol consumption improves the estrogen metabolite profile in adjuvant treated breast cancer patients: a pilot study comparing pre- and post-operative levels
Q43245975	Obesity and angiolymphatic invasion in primary breast cancer.
Q35620661	Postmenopausal circulating levels of 2- and 16α-hydroxyestrone and risk of endometrial cancer
Q64969762	Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.
Q37055548	Risk factors for specific histopathological types of postmenopausal breast cancer in the NIH-AARP Diet and Health Study
Q50132992	The Effect of Flaxseed in Breast Cancer: A Literature Review
Q37139978	Urinary 2/16 estrogen metabolite ratio levels in healthy women: a review of the literature
Q37329197	Urinary estrogen metabolites in women at high risk for breast cancer.